554P Phase I clinical trial of OBP-301, a novel telomerase-specific oncolytic virus, in combination with radiotherapy in esophageal cancer patients
Abstract
OBP-301 is a novel condition-restricted, replication-competent adenovirus derived from human adenovirus type 5 that incorporates a human telomerase reverse transcriptase (hTERT) promoter. This construct causes tumor-specific viral replication and lytic death of a variety of cancer cells, and safety of OBP-301 monotherapy has been confirmed in patients with solid tumor in phase I clinical trial. We conducted phase I clinical trial to evaluate...
Paper Details
Title
554P Phase I clinical trial of OBP-301, a novel telomerase-specific oncolytic virus, in combination with radiotherapy in esophageal cancer patients
Published Date
Sep 1, 2021
Journal
Volume
32
Pages
S612 - S612
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History